Azvudine/Doxitinib mesylate

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameAzvudine/Doxitinib mesylate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsVirion infectivity factor inhibitorsRNA-directed RNA polymerase inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Human immunodeficiency virus type 1 reverse transcriptaseVirion infectivity factor +[5] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes AzvudineDoxitinib mesylate
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHenan Genuine Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHenan Genuine Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A